Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Promsvyazbank may buy M.Video-Eldorado

1/28/25 MVID

Cian applied for delisting of receipts from Moscow Exchange

1/27/25 CIAN

Nornickel reported lower production figures

1/27/25 GMKN

UAC to place 2 trillion shares of additional share issue

1/27/25 UNAC

Zaimer's debt collection agency started collecting debts

1/27/25 ZAYM

M.Video-Eldorado and Avito launched a joint smartphone buyback program

1/27/25 MVID

X5's revenue in 2024 to grow by 24%

1/27/25 X5

Seligdar's revenue in 2024 to grow by 8%

1/27/25 SELG

5Post launches cross-border delivery from China

1/27/25 X5

Lukoil's GCC in Stavropol will be built by the end of 2028 - beginning of 2029

1/24/25 LKOH